Boston-based Novophage has raised $5.7 million in a Series A financing round led by Flybridge Capital Partners. Founder Collective, Boston University, and strategic investors Chevron Technology Ventures and The Kraft Group also participated in the round. The news was first reported by Scott Kirsner of the Boston Globe. Novophage engineers viruses (phages) to combat bacterial contamination in industries like oil and gas, paper, and heating and cooling systems. As part of the financing, Micah Rosenbloom (co-founder of Brontes Technologies) has joined the firm as CEO. Xconomy profiled Novophage back in March 2009, when the company was more focused on therapeutic applications.